All news

Novo Nordisk raises 2026 outlook as Q3 adjusted operating profit climbs 27% at CER to DKK 31.7 billion

GlobeNewswire · · AI-summarised by FinFlash

Novo Nordisk lifted its full-year outlook after third-quarter adjusted operating profit rose 27% at constant currencies, or 34% in kroner, to DKK 31,720 million, beating expectations. Reported sales reached DKK 79,195 million, up 4% at constant currencies. The company now guides 2026 adjusted sales and adjusted operating profit each to between -2% and +2%, citing stronger GLP-1 demand. A year-earlier DKK 9 billion transformation charge flattered the comparison.

So What?

The upgrade should help sentiment toward Novo and the wider obesity trade, though the easy comparison base tempers the headline. Watch the 13:00 CET call for US pricing commentary.

Read original source

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.